Sökning: "CD20"

Visar resultat 1 - 5 av 30 avhandlingar innehållade ordet CD20.

1. 1. Deciphering Binding Patterns of Therapeutic Antibodies with Immune Cells : From Method Development to Application

   Författare :Sina Bondza; Jos Buijs; Marika Nestor; Mark Cragg; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; affinity; binding kinetics; CD20; cell-based assay; immunology; receptor-ligand interaction; therapeutic antibody; Immunologi; Immunology; Medical Cell Biology; Medicinsk cellbiologi;

   Sammanfattning : Reversible binding, for example between signaling molecules and receptors on the cell surface, is one of the main means to communicate information in cellular systems. Knowledge about how molecules interact is crucial for both understanding biological function and for therapeutic intervention. LÄS MER

3. 2. Studies of the Biology of Intrathecal Treatment in Progressive MS

   Författare :Joakim Bergman; Anders Svenningsson; A. Tommy Bergenheim; Jonathan D. Gilthorpe; Joachim Burman; Magnus Andersson; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Progressive Multiple Sclerosis; intrathecal treatment; Ommaya reservoir; anti-CD20 therapy; microdialysis; cerebrospinal fluid; CNS compartments; Progressiv Multipel Skleros; intratekal behandling; Ommaya reservoar; anti-CD20 terapi; mikrodialys; ryggmärgsvätska; sektioner i centrala nervsystemet; Neurology; neurologi;

   Sammanfattning : Background: Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease, affecting the central nervous system (CNS). About 85% of afflicted present with a relapsing-remitting form of the disease (RRMS), for which a breakthrough in treatment was made in 2008 with rituximab, an antibody directed towards CD20, a surface antigen on B-cells. LÄS MER

4. 3. Anti-CD20 therapy in multiple sclerosis : clinical and paraclinical outcomes

   Författare :Alexander Juto; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :;

   Sammanfattning : Multiple sclerosis is a chronic inflammatory disease of the central nervous system and the most common non-traumatic cause of neurological disability in young adults. Rituximab is a B-cell depleting drug targeting the CD20 epitope on B-cells, which drive inflammation in relapsing-remitting multiple sclerosis by acting as antigen-presenting cells to activate T-cell responses against central nervous system autoantigens. LÄS MER

5. 4. Mantle cell lymphoma strategies in primary treatment

   Författare :Alexandra Albertsson Lindblad; Tumörmikromiljö; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; mantle cell lymphoma; registry data; Clinical Trial; Phase I; Clinical Trial; Phase II; rituximab; bendamustine; lenalidomid; ibrutinib; ADCC; in vitro model; TP53 mutations; watchful waiting; mantle cell lymphoma; real-world data; lenalidomide; rituximab; bendamustin; ibrutinib; ADCC; TP53 mutation; CDKN2A; NGS; MIPI; Watchful waiting;

   Sammanfattning : Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. LÄS MER

7. 5. Prognostic role of the tumour microenvironment in esophago-gastric, pancreatic and periampullary adenocarcinoma: B cells and beyond

   Författare :Richard Fristedt; Tumörmikromiljö; []
   Nyckelord :Polymeric immunoglobulin receptor; B cells; Plasma cells; Esophageal adenocarcinoma; gastric adenocarcinoma; Pancreatic ductal adenocarcinoma; Periampullary adenocarcinoma; Prognosis and survival; Immune system;

   Sammanfattning : Cancer development depends on cells aquiring a skillset of limitless growth and finally invasive properties to allow for metastasis, as summarised by the six hallmarks of cancer. Recently four more hallmarks have been added: genomic instability, deregulating cellular metabolism, tumour-promoting inflammation and avoiding immune destruction. LÄS MER